Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Verrica Pharmaceuticals Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
VRCA
Nasdaq
2834
https://verrica.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Verrica Pharmaceuticals Inc
Verrica Pharmaceuticals Announces that YCANTH™ Receives New Chemical Entity Status and Orange Book Listing from the FDA
- Mar 26th, 2024 11:30 am
When Will Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Become Profitable?
- Mar 2nd, 2024 12:18 pm
Verrica Pharmaceuticals Full Year 2023 Earnings: Revenues Beat Expectations, EPS In Line
- Mar 2nd, 2024 12:18 pm
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Q4 2023 Earnings Call Transcript
- Mar 1st, 2024 2:10 pm
Verrica Pharmaceuticals Inc (VRCA) Reports Fourth Quarter and Full-Year 2023 Financial Results
- Feb 29th, 2024 1:11 pm
Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results
- Feb 29th, 2024 12:30 pm
Verrica Pharmaceuticals Announces Participation in the TD Cowen 44th Annual Healthcare Conference
- Feb 27th, 2024 12:30 pm
Verrica Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full-Year 2023 Financial Results on February 29, 2024
- Feb 22nd, 2024 12:30 pm
Verrica Pharmaceuticals Files Lawsuit Against Canadian Drug Manufacturer for False Advertising and Unfair Competition
- Feb 5th, 2024 12:30 pm
Verrica Pharmaceuticals Receives Permanent J-Code (J7354) for YCANTH™ from Centers for Medicare and Medicaid Services
- Jan 29th, 2024 12:30 pm
7 Potential Short-Squeeze Stocks Poised for Rapid Gains
- Jan 23rd, 2024 12:44 am
Verrica Pharmaceuticals Announces Last Patient Dosed in Part 2 of Phase 2 Study of VP-315, a Potential First-in-Class Oncolytic Peptide-Based Immunotherapy, for the Treatment of Basal Cell Carcinoma
- Jan 5th, 2024 12:30 pm
Verrica Pharmaceuticals Announces Receipt of Minutes from Type C Meeting with FDA Regarding Clinical Development of YCANTH™ for the Treatment of Common Warts
- Jan 4th, 2024 12:30 pm
Verrica Pharmaceuticals Announces Specialty Pharmacy Partnership Agreement with Walgreens to Distribute YCANTH™
- Jan 3rd, 2024 12:30 pm
Despite recent sales, Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) insiders remain the largest stockholders with 39% ownership
- Dec 24th, 2023 1:03 pm
Verrica Pharmaceuticals’ Development and Commercialization Partner, Torii Pharmaceutical Co., Ltd., Announces Positive Top-line Results from a Confirmatory Phase 3 Trial of TO-208 for the Treatment of Molluscum Contagiosum in Japan
- Dec 15th, 2023 11:00 am
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Q3 2023 Earnings Call Transcript
- Nov 11th, 2023 3:13 pm
Verrica Pharmaceuticals Announces Presentation at the Jefferies Global Healthcare Conference in London
- Nov 10th, 2023 1:00 pm
Verrica Pharmaceuticals Reports Third Quarter 2023 Financial Results
- Nov 9th, 2023 12:30 pm
Verrica Pharmaceuticals (NASDAQ:VRCA) investors are sitting on a loss of 72% if they invested five years ago
- Oct 26th, 2023 10:55 am
Scroll